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OBJECTIVES Our objectives were to determine whether angiotensin-1 converting enzyme (ACE) inser-
tion/deletion (I/D) polymorphism was associated with the severity of coronary artery disease
(CAD) and its progression/regression in response to fluvastatin therapy in the Lipoprotein
and Coronary Atherosclerosis Study (LCAS) population.
BACKGROUND Genetic factors are involved in susceptibility to CAD. Angiotensin-1 converting enzyme I/D
polymorphism, which accounts for half of the variance of plasma and tissue levels of ACE,
has been implicated in susceptibility to CAD and myocardial infarction (MI).
METHODS Angiotensin-1 converting enzyme genotypes were determined by polymerase chain reaction
(PCR). Fasting plasma lipids were measured and quantitative coronary angiograms were
obtained at baseline and 2.5 years following randomization to fluvastatin or placebo.
RESULTS Ninety-one subjects had DD, 198 ID and 75 II genotypes. The mean blood pressure,
minimum lumen diameter (MLD), number of coronary lesions and total occlusions were not
significantly different at baseline or follow-up among the genotypes. There was a significant
genotype-by-treatment interaction for total cholesterol (p 5 0.018), low-density lipoprotein
cholesterol (LDL-C) (p 5 0.005) and apolipoprotein (apo) B (p 5 0.045). In response to
fluvastatin therapy, subjects with DD, compared with those with ID and II genotypes, had
a greater reduction in total cholesterol (19% vs. 15% vs. 13%), LDL-C (31% vs. 25% vs. 21%)
and apo B (23% vs. 15% vs. 12%). Definite progression was less (14%) and regression was
more common (24%) in DD as compared with those with ID (32% and 17%) and II (33%
and 3%) genotypes (p 5 0.023). Changes in the mean MLD and lesion-specific MLD also
followed the same trend.
CONCLUSIONS Angiotensin-1 converting enzyme I/D polymorphism is associated with the response of
plasma lipids and coronary atherosclerosis to treatment with fluvastatin. Subjects with DD
genotype had a greater reduction in LDL-C, a higher rate of regression and a lower rate of
progression of CAD. (J Am Coll Cardiol 2000;35:89–95) © 1999 by the American College
of Cardiology
Genetic factors play a major role in susceptibility to coro-
nary atherosclerosis, the leading cause of death in the
Western Hemisphere (1). Initial clues implicating genes in
susceptibility to coronary artery disease (CAD) and myo-
cardial infarction (MI) were derived from epidemiological
and twin studies (2). Slack and Evans (2) were among the
first to show that the risk of death from CAD was five- to
seven-fold greater in the first-degree relatives of individuals
with CAD. Similarly, Marenberg et al. (3) showed that the
relative hazard of death from CAD was 8 times higher in a
monozygotic twin and 3.8 times higher in a dizygotic twin
if one’s twin died from premature CAD. The basis for the
interindividual differences in the genetic susceptibility to
atherosclerosis is variations in the nucleotide sequence of the
genes, which are referred to as polymorphisms. A polymor-
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phism can influence the steady state plasma or tissue levels
of the gene product (4) or affect the response of a phenotype
to therapeutic interventions (5,6). It is estimated that
one-fourth to one-half of the total variance in plasma total
cholesterol, high density lipoprotein-cholesterol (HDL-C)
and triglyceride levels are due to genetic polymorphisms (7).
Despite the well-established role of genes in susceptibility
to coronary atherosclerosis, identification of the responsible
genes has been problematic. The commonly used technique
of case-control polymorphism (allelic) association, whereby
the frequency of the variants (alleles) of a candidate gene are
compared in cases and controls, is notorious for spurious
results (8). This is exemplified by the conflicting data on the
possible role of a common insertion/deletion (I/D) poly-
morphism in the angiotensin-1 converting enzyme (ACE)
gene in susceptibility to CAD and MI (4). A better
approach is a longitudinal study of a well-characterized
cohort, which does not have the inherent weaknesses of
case-control allelic association studies (8).
Interest in the role of ACE I/D genotypes in the
susceptibility to CAD stems from observations that the I/D
genotypes account for half of the variability of the plasma,
cellular and tissue levels of ACE (9–11) and from compel-
ling experimental data implicating ACE in vascular ho-
meostasis and atherosclerosis (12). To examine further the
role of ACE in atherosclerosis, we analyzed data from a
longitudinal study of a well-characterized cohort, the Li-
poprotein and Coronary Atherosclerosis Study (LCAS)
population (13), for possible associations of the I/D geno-
types with baseline demographic, biochemical and coronary
angiographic variables and the response of biochemical and
angiographic variables to treatment with the cholesterol
lowering agent fluvastatin, a 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitor.
METHODS
Study population. All subjects provided written informed
consent and the study was approved by the Institutional
Review Board. The study population was comprised of 429
subjects (349 men and 80 women). The design and primary
results of LCAS have been published (13–15). In brief,
patients between 35 and 75 years who had at least one
coronary lesion causing 30% to 75% diameter stenosis and
low density lipoprotein-cholesterol (LDL-C) of 115–190
mg/dl despite diet were randomized to 40 mg fluvastatin
daily or placebo. Total cholesterol, LDL-C, HDL-C,
triglyceride and apolipoprotein (apo) levels were measured
in all subjects at baseline and throughout the study. Subjects
underwent quantitative coronary angiography upon enroll-
ment (n 5 429) and 2.5 years following randomization (n 5
340). The primary end point was within-subject per-lesion
change in the minimum lumen diameter (MLD) of quali-
fying lesions, defined by MLD $25% of the reference
lumen diameter at baseline and MLD $0.8 mm less than
the reference lumen diameter at either baseline or follow-
up. Subjects were also categorized as having definite pro-
gression, definite regression or mixed angiographic change.
Definite progression was defined as $1 qualifying lesion
with MLD decrease $0.4-mm, including new total occlu-
sions and no qualifying lesion with MLD increase $4 mm.
Definite regression was defined as $1 qualifying lesion with
MLD increase $0.4 mm, no qualifying lesion with MLD
decrease $0.4 mm and no new total occlusion. Subjects that
showed neither definite progression nor definite regression
were classified as having mixed change. Clinical events
monitored were definite or probable MI, unstable angina
requiring hospitalization, percutaneous transluminal coro-
nary angioplasty, coronary artery bypass grafting, all-cause
mortality and cardiovascular mortality.
Genotyping. Laboratory personnel who had no knowledge
of the clinical data performed the genotyping and two
individuals read the genotypes. Angiotensin-1 converting
enzyme genotypes were determined using polymerase chain
reaction (PCR) (16) in 364/429 (85%) subjects. In 54
subjects DNA samples were not available, and in the
remaining 11 subjects, the PCR reactions did not work.
Each PCR reaction contained 100 hg of DNA template,
0.125 mM of each primer, 200 uM of 4dNTPs, 1 U of Taq
DNA polymerase and 1.5 mM of MgCl2 and 5% dimethyl
sulfoxide (DMSO). DNA was amplified for 30 cycles, each
comprised of denaturation at 94°C for 1 min, annealing at
58°C for 1 min, extension at 72°C for 1 min with a final
extension time of 3 min. To avoid possible mistyping of the
genotypes, in addition to using DMSO (17), those with the
DD genotype were reanalyzed by PCR using a set of
insertion-specific primers (18). The PCR products were
separated by electrophoresis on 2% agarose gel and identi-
fied by ethidium bromide staining.
Statistical analysis. Continuous variables were expressed
as mean 6 SD (with the exception of lesion-specific MLD
which was expressed as mean 6 SE) and their differences
among genotypes were compared by analysis of variance
(ANOVA). Variables that were unsuited for ANOVA
because of inequality of variance were analyzed by the
Kruskal-Wallis test. Distribution of categorical variables
Abbreviations and Acronyms
ACE 5 angiotensin-1 converting enzyme
ANOVA 5 analysis of variance
apo 5 apolipoprotein
CAD 5 coronary artery disease
DMSO 5 dimethyl sulfoxide
HDL-C 5 high density lipoprotein-cholesterol
HMG-CoA 5 3-hydroxy-3-methylglutaryl coenzyme A
I/D 5 insertion/deletion
LCAS 5 Lipoprotein and Coronary
Atherosclerosis Study
LDL-C 5 low density lipoprotein-cholesterol
MI 5 myocardial infarction
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among genotypes was compared using chi-square or Fisher’s
exact tests. To determine the association of ACE genotypes
with response to fluvastatin treatment, mean changes in
lipid levels and MLD among the genotypes were compared
using ANOVA. The ANOVA performed in this study
utilizes Yates’ weighted squares of means technique, which
has the ability to obtain the proper sums of squares for
testing main and interaction effects on data with dispropor-
tional unequal subclass sizes. In addition, analyses were
repeated using the following assigned weights to the geno-
types according to their known biological association with
plasma, cellular and tissue levels of ACE (9–11): DD 5 2,
ID 5 1.5, II 5 1. The results of weighted analysis are
reported when they did not differ substantially from the
results of unweighted analysis, otherwise both results are
reported. Statistical analysis was performed using STATA,
version 5.0, (Stata Corporation, College Station, Texas).
RESULTS
ACE genotypes. The products of D and I alleles were
identified by the presence of 190 and 490 base pair bands on
agrose gel electrophoresis, respectively. Repeat PCR using
insertion-specific primers did not identify genotype mistyp-
ing, which may be due to the routine use of DMSO in the
PCR reaction (17). The frequencies of D and I alleles were
0.52 and 0.48, respectively. The frequencies of genotypes
are shown in Table 1.
Demographic data. The baseline characteristics of subjects
according to genotype are shown in Table 1. The mean
systolic and diastolic blood pressure, mean MLD and the
number of subjects with $1 qualifying lesion or total
occlusions were not significantly different among the geno-
types. Subjects with the ID genotype had a lower proportion
of previous MI (33%) as compared with DD (50%) and II
(51%) genotypes (p 5 0.006). However, this observation is
not in accord with the genetic gradient or the known
biological association of the ACE I/D genotypes with
plasma and tissue levels of ACE (9–11).
Plasma lipid levels. Table 2 shows the baseline and final
values and percent change of lipid levels in the placebo and
fluvastatin treatment groups according to genotype. There
was a significant genotype-by-treatment interaction for total
cholesterol (p 5 0.018), LDL-C (0.005), and apo B (p 5
0.045). Subjects with the DD genotype, as compared with
subjects with the ID and II genotypes, had a greater
reduction in plasma levels of total cholesterol (19% vs. 15%
vs. 13%), LDL-C (31% vs. 25% vs. 21%) and apo B (23% vs.
15% vs. 12%), respectively, in response to fluvastatin ther-
apy. The magnitude of the reduction in total cholesterol,
LDL-C and apo B followed the genetic gradient and the
biological effect of the I/D genotypes on tissue, cellular and
plasma levels of ACE (DD.ID.II) (9–11).
A total of 63 subjects (25 in the placebo group and 38 in
the fluvastatin group) were on ACE inhibitor therapy at
baseline or during the study. The distribution of subjects
taking ACE inhibitors among the ACE genotypes was not
significantly different (Table 1). When controlled for treat-
ment with ACE inhibitors, significant interactions between
ACE genotypes and response of the plasma cholesterol (p 5
0.003), LDL-C (p 5 0.014) and apo B (p 5 0.041) to
treatment with fluvastatin persisted. Similarly, exclusion of
subjects who were on ACE inhibitors did not affect the
overall results. In addition, the distribution of genotypes did
not differ significantly in this group as compared with the
remainder of the subjects, and treatment with ACE inhib-
itors had no significant effect on the baseline plasma lipid
levels among the subjects with different ACE genotypes
(data not shown).
Progression or regression of CAD and clinical events.
Angiographic results (n 5 308) are shown in Table 3.
Concordant with the influence of ACE I/D genotype on
the response of plasma LDL-C levels to fluvastatin, subjects
with the DD genotype were less likely to have definite
progression (14%) and more likely to have definite regres-
sion (24%) compared with those with ID (32% progression
and 17% regression) or II (33% progression and 3% regres-
sion) genotypes (p 5 0.023). Mean MLD also increased in
those with the DD genotype (increase: 0.05 6 0.20 mm)
indicative of regression, whereas it decreased in those with
the ID (decrease: 0.04 6 0.26 mm) or II (decrease: 0.01 6
Table 1. Baseline Characteristics of Subjects According to
Ace Genotypes
ACE I/D Genotypes
DD ID II
n 5 364 91 198 75
Age (yrs) 58.9 6 7.4 58.8 6 7.6 58.8 6 8.3
Men 76 (84) 164 (83) 63 (84)
White 82 (90) 177 (89) 69 (92)
Height (m) 1.73 6 0.08 1.73 6 0.09 1.74 6 0.08
Weight (kg) 83.0 6 15.6 85.0 6 16.0 86.1 6 14.0
BMI (kg/m2) 27.6 6 4.3 28.2 6 4.5 28.4 6 4.0
Waist/hip ratio 0.91 6 0.06 0.91 6 0.07 0.91 6 0.07
Previous MI 45 (50) 66 (33) 38 (51)
Diabetes mellitus 6 (7) 5 (3) 3 (4)
Systolic BP
(mm Hg)
123.8 6 14.6 124.4 6 15.3 124.5 6 15.9
Diastolic BP
(mm Hg)
78.1 6 9.0 76.6 6 9.0 76.3 6 9.3
Smoker 21 (23) 36 (18) 16 (21)
ACE inhibitors 16 (18) 36 (18) 11 (15)
# of qualifying
lesions
2.97 6 2.24 2.69 6 2.0 2.44 6 1.6
# of total occlusions 0.46 6 0.82 0.29 6 0.60 0.32 6 0.62
$1 qualifying lesion 77 (85) 168 (85) 62 (83)
$1 total occlusion 29 (32) 46 (23) 19 (25)
Mean MLD (mm) 1.66 6 0.35 1.68 6 0.40 1.67 6 0.41
Values are presented as either Mean 6 SD or n (%).
ACE 5 angiotensin-I converting enzyme; BMI 5 body mass index; MI 5
myocardial infarction; BP 5 blood pressure; MLD 5 minimum lumen diameter.
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0.26) genotypes, which indicate progression. Lesion-specific
MLD also followed the same trend. These differences did
not reach statistical significance.
Of the 364 subjects, 52 (14%) had clinical events. The
distribution of the clinical events among the genotypes was
not significantly different (Table 3).
DISCUSSION
Findings. The main finding of this study is that ACE I/D
genotypes influence the response of plasma lipids to treat-
ment with fluvastatin. Subjects with the DD genotype had
a greater reduction in plasma levels of LDL-C than those
with ID or II genotypes. Similarly, the reductions in plasma
levels of total cholesterol and apo B were also greater in
subjects with the DD genotype. The interaction between
the ACE I/D genotypes with the response of plasma lipids
to fluvastatin therapy exhibited a gene-dose effect and was in
accord with the known biological association of the I/D
genotypes with plasma, cellular and tissue levels of ACE
(DD.ID.II) (9–11). Consistent with a greater reduction
in LDL-C in response to fluvastatin therapy, subjects with
the DD genotype also exhibited a higher rate of regression
and a lower rate of progression of coronary atherosclerosis as
determined by quantitative coronary angiography. Another
main finding of this study is that the ACE genotypes were
not associated with baseline severity of CAD, progression or
regression of coronary atherosclerosis in the placebo group
or clinical events.
In the entire LCAS population, treatment with fluva-
statin reduced the mean LDL-C and increased the mean
HDL-C by 27% and 6%, respectively (13). The mean MLD
of qualifying lesions showed significantly less progression in
Table 2. Influence of ACE Genotypes on the Baseline and Final Plasma Lipid Levels
Genotypes
N 5 360
Placebo Fluvastatin
DD 55 ID 87 II 35 DD 33 ID 110 II 40
TC:
BL 220.7 6 25.0 220.4 6 24.5 218.8 6 25.5 224.2 6 25.4 222.0 6 25.1 217.7 6 19.2
FU 223.4 6 34.4 216.9 6 32.9 209.4 6 30.8 180.1 6 21.1 187.4 6 33.5 188.9 6 34.2
% D* 1.5 6 13.0 21.3 6 12.6 23.7 6 13.6 219.2 6 8.7 215.2 6 13.9 213.0 6 13.2
HDL-C:
BL 44.2 6 9.2 45.2 6 12.6 43.3 6 9.3 44.7 6 12.9 44.0 6 11.5 39.9 6 9.4
FU 45.5 6 10.0 46.3 6 13.9 44.7 6 9.1 48.2 6 10.8 47.0 6 11.5 44.2 6 12.7
% D 3.5 6 15.2 3.1 6 15.6 4.4 6 15.7 10.0 6 14.2 8.6 6 17.3 10.7 6 13.2
LDL-C:
BL 143.1 6 21.4 145.6 6 19.3 143.3 6 20.6 145.2 6 20.7 146.8 6 20.3 141.9 6 18.8
FU 142.1 6 28.4 138.7 6 29.4 129.1 6 23.6 99.9 6 20.1 109.4 6 27.2 110.9 6 27.2
% D* 20.1 6 17.2 24.4 6 17.5 28.8 6 18.2 230.8 6 12.0 224.9 6 18.3 221.3 6 19.0
Trig:
BL 169.5 6 67.3 147.5 6 45.0 162.8 6 53.6 171.6 6 65.3 156.4 6 56.2 176.5 6 62.9
FU 180.8 6 81.4 159.7 6 71.4 173.3 6 76.7 160.4 6 63.9 156.5 6 84.2 168.0 6 68.5
% D 10.7 6 39.3 10.6 6 42.8 8.1 6 35.1 23.3 6 29.6 1.7 6 44.7 20.6 6 33.2
ApoA-I:
BL 135.4 6 25.2 134.6 6 30.1 132.2 6 24.2 137.5 6 5 131.7 6 26.0 121.3 6 23.0
FU 135.1 6 26.5 135.2 6 32.4 134.1 6 26.8 142.4 6 34.8 137.8 6 26.8 134.7 6 37.4
% D 0.5 6 15.2 1.2 6 15.1 2.1 6 13.9 3.7 6 14.3 6.6 6 20.7 11.5 6 22.1
Apo-B:
BL 135.3 6 21.6 132.6 6 21.4 131.8 6 17.2 141.5 6 16.8 138.0 6 21.4 133.8 6 17.4
FU 142.4 6 25.8 137.5 6 27.6 134.0 6 23.6 109.1 6 18.0 116.4 6 24.5 116.0 6 15.3
% D* 6.3 6 16.8 5.0 6 20.9 2.7 6 19.8 222.6 6 10.9 214.7 6 16.9 212.3 6 13.2
Lp(a):
BL 32.5 6 29.0 40.4 6 37.6 31.1 6 28.9 45.3 6 40.1 36.6 6 32.5 34.1 6 32.1
FU 35.6 6 38.1 45.4 6 47.8 30.3 6 32.0 50.1 6 49.1 41.3 6 42.1 34.4 6 35.6
% D 26.8 6 35.3 20.6 6 31.3 28.1 6 30.9 0.3 6 33.9 21.6 6 37.9 26.5 6 34.5
All values are mg/dl and are represented as mean 6 SD.
BL 5 baseline; FU 5 final follow up; TC 5 total cholesterol; TG 5 triglyceride. Significant genotype-by-treatment interaction for TC (p 5 0.018), LDL-C (p 5 0.005)
and apo B (p 5 0.045). The p values are derived from the weighted analyses and do not differ significantly from the unweighted analyses (TC: p 5 0.0202, LDL-C: p 5 0.0052,
apo B: p 5 0.0550).
The %D was calculated as follows:
%D 5 O
i51
n
FUi 2 BLi
BLi
n 3 100; where i 5 number of subgroup patients.
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the fluvastatin group. There were also fewer subjects with
the progression and more subjects with the regression of
coronary atherosclerosis in the fluvastatin treatment group
as compared with the placebo group (13). A similar trend,
which was not statistically significant, was also observed in
clinical event rates (13). The greatest angiographic and
clinical benefit was observed in subjects with low HDL-C
(15).
Evidence favoring a true association. The observed asso-
ciation between ACE I/D genotypes and the response of
plasma lipids to treatment with fluvastatin was unexpected
and requires further validation in additional data sets.
Nonetheless, it is likely a true association for the following
reasons. The strength of the observed association (p 5
0.005) is considered strong (8,19). The concordant associ-
ations with several variables, namely, three related plasma
lipid components and angiographic indexes of progression/
regression also favor a true association (8). In addition, the
presence of a gene-dose effect (genetic gradient), which is
consistent with the association of the ACE I/D genotypes
with plasma, cellular and tissue levels of ACE (biological
gradient) (9–11) further supports a true association. Fur-
thermore, the prospective nature of this longitudinal study
and the detailed characterization of the subjects reduce the
chance of a spurious association (8).
A total of 108 (including 79 subjects in whom angio-
graphic data are available) in the LCAS were also treated
with cholestyramine. To exclude the possible confounding
effect of cholestyramine therapy on the results of this study,
the distribution of ACE genotypes among subjects treated
with or without cholestyramine was compared and did not
differ significantly (data not shown). In addition, possible
genotype-by-treatment (with cholestyramine) interactions
were analyzed and no significant interactions were detected
(data not shown). Regarding the possible confounding effect
of patient compliance, we note that the compliance rate
with fluvastatin treatment, defined as medication compli-
ance of at least 80%, in the entire LCAS population was
95%. Therefore, it is unlikely that the overall results would
be significantly affected by the presence of possible unex-
pected differences in the compliance rates among the sub-
jects with different ACE genotypes.
Potential limitations. The design of LCAS (and hence,
the choice of end points) had been determined prior to the
decision to perform genetic analyses and therefore, this
study is a secondary data analysis. In addition, no adjust-
ment was made for multiple testing as the examination of
each variable for the possible existence of a significant
genotype-by-treatment interaction is considered a form of
multiple unrelated hypotheses (20). According to J.W.
Tukey (20), it is only mandatory to adjust the significance
level for multiple hypotheses when the hypotheses being
tested are not fully independent of one another (20). In view
of multiple testing, significant p values (p , 0.05) should be
regarded as potential associations.
As it is true for all association studies, the results of this
study require confirmation in additional data sets. In this
regard, the preliminary analysis of a similar study showed no
association between the plasma lipid levels and response to
treatment with pravastatin (21). However, patients with the
DD genotype showed a blunted effect of pravastatin therapy
on coronary atherosclerosis despite identical plasma lipid
response (21).
We could not determine the ACE genotypes in 65 of the
429 subjects due to reasons of either unavailability of DNA
samples or PCR reactions not working. This might have
created unequal treatment sample sizes among the placebo
and treatment groups. The loss of genotyping data is
essentially random and is unlikely to account for the
observed genotype-treatment interactions. In addition, the
Table 3. Influence of ACE Genotypes on Progression or Regression of Coronary Lesions and Clinical events
Genotypes
Placebo Fluvastatin
DD ID II DD ID II
n 5 308 48 74 29 29 95 33
$1 new lesion 20 (42) 26 (35) 8 (28) 6 (21) 28 (29) 8 (24)
$1 new total occlusion* 6 (12) 1 (1) 4 (14) 0 (0) 4 (4) 2 (6)
Categorical angiographic change**
Progression (%) 19 (40) 25 (34) 16 (55) 4 (14) 30 (32) 11 (33)
Regression (%) 3 (6) 7 (9) 2 (7) 7 (24) 16 (17) 1 (3)
Mixed change (%) 26 (54) 42 (57) 11 (38) 18 (62) 49 (52) 21 (64)
delta MLD (mm) 20.13 6 0.22 20.08 6 0.24 20.17 6 0.29 0.05 6 0.20 20.04 6 0.26 20.11 6 0.26
Lesion-specific delta MLD (mm) 20.14 6 0.03 20.11 6 0.03 20.19 6 0.05 0.04 6 0.04 20.05 6 0.02 20.11 6 0.05
Clinical events
All subjects (52/364*) 6 (11) 16 (18) 6 (17) 6 (17) 13 (12) 5 (13)
Angiographic group (36/308) 2 (4) 11 (15) 5 (17) 3 (10) 11 (12) 4 (12)
Values for delta MLD are presented as mean 6 SD, for lesion-specific delta MLD as mean 6 SE and for all others as n (%).
*p 5 0.009 between ID vs. other genotypes within placebo group. **p 5 0.052 differences between genotypes within fluvastatin group (for progression vs. regression: p 5
0.023).
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statistical methods used in this study takes into account
disproportional unequal subclasses sizes.
Possible mechanisms. This study shows a gene-treatment
interaction without exploring the responsible mechanism(s).
It is also not known whether treatment-genotype interac-
tion is specific for fluvastatin and whether it is common to
other HMG-CoA reductase inhibitors remains to be ex-
plored. Existing data do not provide a clear biologically
plausible mechanism to explain the observed association.
However, they indicate complex interactions between an-
giotensin II and bradykinin, the products of ACE enzy-
matic activity and LDL-C peroxidation as well as the
activity of the HMG-CoA reductase inhibitors (22,23). It is
well-established that angiotensin II increases not only the
macrophage-mediated oxidation of LDL (24), but also the
cellular uptake of oxidized LDL by the scavenger recep-
tors (25,26). In contrast, fluvastatin inhibits LDL oxida-
tion and stimulates the removal of LDL from the
circulation (27). It is intriguing to speculate that the
differences in the plasma, cellular and tissue concentra-
tions of ACE (9 –11), angiotensin II and bradykinin in
subjects with different genotypes affect LDL peroxida-
tion, removal of the oxidized LDL by the macrophages,
the rate of receptor-mediated uptake of the LDL or the
pharmacokinetics of fluvastatin itself.
Gene-treatment interactions. Although this study is the
first to show an interaction between ACE I/D genotypes
and the response of plasma lipids to therapy, interactions
between genetic polymorphisms and drug efficacy have been
recognized for many years (28). The classic example is that
of cytochrome P450 isozymes, which determine interindi-
vidual variations in the metabolism of many drugs in the
liver, including the HMG-CoA reductase inhibitors (28).
With regard to lipids metabolism, polymorphisms in genes
coding for apo B, apo A1/CIII and apo E have been shown
to influence the response of plasma lipids to treatment with
gemfibrozil (29) and probucol (30), respectively. Similarly,
polymorphisms in the genes coding for cholesteryl ester
transfer protein, apo E, apo A-1, apo A-IV have been
associated with response of plasma lipids to dietary inter-
ventions (5,6,31). Other examples of gene-treatment inter-
action include polymorphisms in the neurotransmitter ser-
tonin type IIA receptor and alpha-adducin genes which are
associated with the clinical response to antipsychotic drugs
in schizophrenic patients (32) and to diuretics in hyperten-
sive patients (33), respectively. Thus, genetic polymor-
phisms, in part, form the basis for interindividual variations
in the response to drug therapy.
In summary, the results of this prospective study show
that the I/D variants of the ACE gene are associated with
the response of plasma lipids and coronary atherosclerosis to
treatment with fluvastatin. Subjects the DD genotype ex-
hibited a greater reduction in LDL-C, a higher rate of
regression and a lower rate of progression of coronary
atherosclerosis.
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